At-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD)

Transcription

1 At-A-Glance Outpatient Management Reference f Chronic Obstructive Pulmonary Disease (COPD) BASED ON THE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT AND PREVENTION OF COPD GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD) REVISED 2011 Please refer to the GOLD Rept (revised 2011) at

2 DIAGNOSING COPD A diagnosis of COPD should be considered in any individual who has dyspnea, chronic cough sputum production, and/ a histy of exposure to risk facts f the disease, especially cigarette smoking. Table 1. Key Indicats f Considering a Diagnosis of COPD Consider COPD, and perfm spirometry, if any of these indicats are present in an individual over age 40. These indicats are not diagnostic themselves, but the presence of multiple key indicats increases the probability of a diagnosis of COPD. Spirometry is required to establish a diagnosis of COPD. Dyspnea that is: Chronic cough: Progressive (wsens over time). Characteristically wse with exercise. Persistent. May be intermittent and may be unproductive. Chronic sputum production: Any pattern of chronic sputum production may indicate COPD. Histy of exposure to risk facts: Tobacco smoke (including popular local preparations). Smoke from home cooking and heating fuels. Occupational dusts and chemicals. Family histy of COPD Spirometry is required to make a clinical diagnosis of COPD; the presence of a postbronchodilat FEV 1 /FVC < 0.70 confirms the presence of persistent airflow limitation and thus of COPD. All health care wkers who care f COPD patients should have access to spirometry.

3 ASSESSMENT OF COPD The goals of COPD assessment are to determine the severity of the disease, its impact on patient s health status, and the risk of future events (exacerbations, hospital admissions, death) in der to guide therapy. Assess the following aspects of the disease separately: Symptoms Degree of airflow limitation (using spirometry) Risk of exacerbations Combidities Assess Symptoms: Validated questionnaires such as the COPD Assessment Test (CAT) the Modified British Medical Research Council (mmrc) breathlessness scale should be used to assess symptoms. Assess Degree of Airflow Limitation Using Spirometry: Table 2 provides the classification of airflow limitation severity in COPD. Table 2. Classification of Severity of Airflow Limitation in COPD (Based on Post-Bronchodilat FEV 1 ) In patients with FEV1/FVC < 0.70: GOLD 1: Mild FEV 1 80% predicted GOLD 2: Moderate 50% FEV 1 < 80% predicted GOLD 3: Severe 30% FEV 1 < 50% predicted GOLD 4: Very Severe FEV 1 < 30% predicted Assess Risk of Exacerbations: An exacerbation of COPD is defined as an acute event characterized by a wsening of the patient s respiraty symptoms that is beyond nmal day-to-day variations and leads to a change in medication. The best predict of having frequent exacerbations (2 me per year) is a histy of previous treated events; the risk of exacerbations also increases as airflow limitation wsens. Assess Combidities: Cardiovascular diseases, osteoposis, depression and anxiety, skeletal muscle dysfunction, metabolic syndrome, and lung

4 cancer among other diseases occur frequently in COPD patients. These combid conditions may influence mtality and hospitalizations, and should be looked f routinely and treated appropriately. Combined Assessement of COPD: Table 3 provides a rubric f combining these assessments to improve management of COPD. Symptoms: Less Symptoms (mmrc 0-1 CAT < 10): patient is (A) (C) Me Symptoms (mmrc 2 CAT 10): patient is (B) (D) Airflow Limitation: Low Risk (GOLD 1 2): patient is (A) (B) High Risk (GOLD 3 4): patient is (C) (D) Exacerbations: Low Risk ( 1 per year): patient is (A) (B) High Risk ( 2 per year): patient is (C) (D) Table 3. Combined Assessment of COPD (When assessing risk, choose the highest risk accding to GOLD grade exacerbation histy.) Patient A B C D Characteristic Low Risk Less Symptoms Low Risk Me Symptoms High Risk Less Symptoms High Risk Me Symptoms Spirometric Classification Exacerbations per year mmrc CAT GOLD < 10 GOLD GOLD < 10 GOLD

5 MANAGEMENT OF STABLE COPD Once COPD has been diagnosed, effective management should be based on an individualized assessment of current symptoms and future risks: Relieve symptoms Improve exercise tolerance REDUCE SYMPTOMS Improve health status and Prevent disease progression Prevent and treat exacerbations REDUCE RISK Reduce mtality These goals should be reached with minimal side effects from treatment, a particular challenge in COPD patients because they commonly have combidities that also need to be carefully identified and treated. Bronchodilats Recommendations: F both beta 2 s and anticholinergics, long-acting fmulations are preferred over sht-acting fmulations. The combined use of sht- long-acting beta 2 s and anticholinergics may be considered if symptoms are not improved with single agents. Based on efficacy and side effects, inhaled bronchodilats are preferred over al bronchodilats. Based on evidence of relatively low efficacy and greater side effects, treatment with theophylline is not recommended unless other bronchodilats are not available unaffdable f longterm treatment. Cticosteroids and Phosphodiesterase-4 Inhibits Recommendations There is no evidence to recommend a sht-term therapeutic trial with al cticosteroids in patients with COPD to identify those who will respond to inhaled cticosteroids other medications. Long-term treatment with inhaled cticosteroids is recommended f patients with severe and very severe airflow limitation and f patients with frequent exacerbations that are not adequately controlled by long-acting bronchodilats. Long-term monotherapy with al cticosteroids is not recommended in COPD. Long-term monotherapy with inhaled cticosteroids is not recommended in COPD because it is less effective than the combination of inhaled cticosteroids with long-acting beta 2 - agonists. The phosphodiesterase-4 inhibit roflumilast may also be used to reduce exacerbations f patients with chronic bronchitis, severe and very severe airflow limitation, and frequent exacerbations that are not adequately controlled by long-acting bronchodilats.

6 Table 4: Pharmacologic Therapy f Stable COPD* *Medications in each box are mentioned in alphabetical der and therefe not necessarily in der of preference. **Medications in this column can be used alone in combination with other options in the First and Second Choice columns Glossary: SA: sht-acting LA: long-acting ICS: inhaled cticosteroid PDE-4: phosphodiesterase-4 prn: when necessary Patient Group A B C D FIRST CHOICE SECOND CHOICE ALTERNATIVE CHOICE** SA anticholinergic prn prn LA anticholinergic ICS + LA anticholinergic ICS + LA anticholinergic LA anticholinergic and SA anticholinergic LA anticholinergic and LA anticholinergic and ICS and LA anticholinergic ICS + and LA anticholinergic ICS + and PDE-4 inhibit LA anticholinergic and LA anticholinergic and PDE-4 inhibit Theophylline and/ SA anticholinergic PDE-4 inhibit and/ SA anticholinergic Theophylline Carbocysteine and/ SA anticholinergic Theophylline

7 Table 5. Fmulations and Typical Doses of COPD Medications* Solution f Vials f Duration Inhaler (µg) Drug Nebulizer Oral Injection of Action (mg/ml) (mg) (hours) Beta 2 s Sht-acting Fenoterol (MDI) % (Syrup) 4-6 Levalbuterol (MDI) 0.21, Salbutamol (albuterol) 100, mg (Pill), %(Syrup) 0.1, Terbutaline 400, 500 (DPI) 2.5, 5 mg (Pill) 4-6 Long-acting Fmoterol Arfmoterol Indacaterol (DPI) 24 Salmeterol Tulobuterol 2 mg (transdermal) 24 Anticholinergics Sht-acting Ipratropium bromide 20, 40 (MDI) Oxitropium bromide 100 (MDI) Long-acting Tiotropium 18 (DPI), 5 (SMI) 24 Combination sht-acting beta 2 s plus anticholinergic in one inhaler Fenoterol/Ipratropium 200/80 (MDI) 1.25/ Salbutamol/ Ipratropium 75/15 (MDI) 0.75/ Methylxanthines Aminophylline mg (Pill) 240 Variable, up to 24 Theophylline (SR) mg (Pill) Variable, up to 24 Inhaled cticosteroids Beclomethasone Budesonide 100, 200, 400 (DPI) , 0.5 Fluticasone Combination long-acting beta 2 s plus cticosteroids in one inhaler Fmoterol/Budesonide 4.5/160 (MDI) 9/320 (DPI) 50/100, 250, 500 (DPI) Salmeterol/Fluticasone 25/50, 125, 250 (MDI) Systemic cticosteroids Prednisone 5-60 mg (Pill) Methyl-prednisolone 4, 8, 16 mg (Pill) Phosphodiesterase-4 inhibits Roflumilast 500 mcg (Pill) 24 MDI=metered dose inhaler; DPI=dry powder inhaler; SMI=smart mist inhaler *Not all fmulations are available in all countries; in some countries, other fmulations may be available. Fmoterol nebulized solution is based on the unit dose vial containing 20 mcg in a volume of 2.0 ml

8 The Global Initiative f Chronic Obstructive Lung Disease is suppted by unrestricted educational grants from: Almirall AstraZeneca Boehringer Ingelheim Chiesi Dey Pharmaceuticals Fest Labaties GlaxoSmithKline Grupo Ferrer Merck Sharp and Dohme Nonin Medical Novartis Nycomed Pearl Therapeutics Pfizer GOLD 2011 source documents are at Global Initiative f Chronic Obstructive Lung Disease Copies of this document are available at